Cellectis SA
(LTS:0WA2)
€
1.897
-0.02 (-1.04%)
Market Cap: 188.58 Mil
Enterprise Value: 137.41 Mil
PE Ratio: 0
PB Ratio: 1.62
GF Score: 38/100 - Q1 2024 Cellectis SA Earnings Call TranscriptMay 29, 2024€2.4 (-8.40%)Earnings
- Q3 2023 Cellectis SA Earnings Call TranscriptNov 07, 2023€2.48 (-1.47%)Earnings
- Cellectis SA at Jefferies Cell & Genetic Medicine Summit TranscriptSep 26, 2023
- Q2 2023 Cellectis SA Earnings Call TranscriptAug 04, 2023€1.78 (-0.28%)Earnings
- Cellectis SA at Goldman Sachs Healthcare Conference TranscriptJun 15, 2023
- Q1 2023 Cellectis SA Earnings Call TranscriptMay 05, 2023€1.8 (+2.04%)Earnings
- Cellectis SA at Barclays Global Healthcare Conference TranscriptMar 14, 2023
- Q4 2022 Cellectis SA Earnings Call TranscriptMar 09, 2023€2.03 (-4.22%)Earnings
- Cellectis SA Corporate Analyst Meeting (Virtual) TranscriptDec 13, 2022
- Q3 2022 Cellectis SA Earnings Call TranscriptNov 04, 2022€2.4 (-5.10%)Earnings
- Atara Biotherapeutics Inc, Cellectis SA and 2Seventy Bio Inc at Citi BioPharma Conference- Panel TranscriptSep 07, 2022
- Q2 2022 Cellectis SA Earnings Call TranscriptAug 05, 2022€3.27 (+9.19%)Earnings
- Cellectis SA at Goldman Sachs Global Healthcare Conference TranscriptJun 16, 2022
- Cellectis SA at JMP Securities Life Sciences Conference TranscriptJun 16, 2022
- Q1 2022 Cellectis SA Earnings Call TranscriptMay 13, 2022€2.96 (+0.85%)Earnings
- Cellectis SA at Barclays Global Healthcare Conference TranscriptMar 17, 2022
- Q4 2021 Cellectis SA Earnings Call TranscriptMar 04, 2022€3.43 (-4.14%)Earnings
- Cellectis SA at Barclays Gene Editing & Gene Therapy Summit (Virtual) TranscriptNov 15, 2021
- Q3 2021 Cellectis SA Earnings Call TranscriptNov 05, 2021€10.46 (+0.10%)Earnings
- Cellectis SA at Citi BioPharma Conference (Virtual) TranscriptSep 09, 2021
- Q2 2021 Cellectis SA Earnings Call TranscriptAug 06, 2021€11.88 (+2.19%)Earnings
- Cellectis SA at Barclays Global Healthcare Conference (Virtual) TranscriptMar 10, 2021
- Q4 2020 Cellectis SA Earnings Call TranscriptMar 05, 2021€14.44 (-13.27%)Earnings
- Cellectis SA at Barclays Virtual Gene Editing & Gene Therapy Summit - Presentation TranscriptNov 16, 2020
- Q3 2020 Cellectis SA Earnings Call TranscriptNov 06, 2020€14.11 (-4.14%)Earnings
- Cellectis SA at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) TranscriptSep 17, 2020
- Q2 2020 Cellectis SA Earnings Call TranscriptAug 06, 2020€14.54 (-0.95%)Earnings
- Cellectis SA Chardan Leadership Call TranscriptMay 27, 2020
- Q1 2020 Cellectis SA Earnings Call TranscriptMay 07, 2020€12.86 (-0.46%)Earnings
- Q4 2019 Cellectis SA Earnings Call TranscriptMar 05, 2020€14 (-2.98%)Earnings
- Q3 2019 Cellectis SA Earnings Call TranscriptNov 07, 2019€11.53 (+1.45%)Earnings
- Cellectis SA at Citi Biotech Conference TranscriptSep 04, 2019
- Cellectis SA at Goldman Sachs Global Healthcare Conference TranscriptJun 13, 2019
- Cellectis SA at Barclays Global Healthcare Conference TranscriptMar 13, 2019
- Q4 2018 Cellectis SA Earnings Call TranscriptMar 12, 2019€16.23 (+2.33%)Earnings
Cellectis SA at JMP Securities Life Sciences Conference Transcript
Jun 16, 2022 / 02:00PM GMT
Release Date Price:
€2.19
(-6.64%)
Silvan Türkcan
JMP Securities LLC - Analyst
Welcome back to the JMP Life Sciences Conference, the second day. My name is Silvan Türkcan. I'm a senior analyst covering precision medicines here. It's my pleasure to host Cellectis at today's conference. André Choulika, CEO and Founder; and Arthur Stril, Chief Business Officer. Thank you. Thanks for joining us today.
AndrÃ;Choulika
Cellectis SA - CEO & Board Director
© -
Thanks for inviting us.
Arthur Stril
Cellectis SA - Chief Business Officer
Thanks for inviting us.
Questions & Answers
Silvan Türkcan;AndrÃ;Choulika
JMP Securities LLC - Analyst;Cellectis SA - CEO & Board Director<
So, obviously, maybe we could start with your view about the allogeneic CAR T space coming out of all the data sets that we've seen at ACR, EHA, ASCO. The recent days, there have been a lot of updates. So can you just tell us how -- where are we now with ALLO?
©
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)